Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Treatment-Related Fatigue Widespread, But Undertreated, Seldom Discussed

July 1, 2001
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 7
Volume 10
Issue 7

BETHESDA, Maryland-Fatigue among cancer patients "is an important problem, and it’s a legitimate topic for clinical investigation," National Cancer Institute Clinical Director Gregory A. Curt, MD, told Oncology News International, lamenting, " I don’t think it’s high on the radar for the physicians."

BETHESDA, Maryland—Fatigue among cancer patients "is an important problem, and it’s a legitimate topic for clinical investigation," National Cancer Institute Clinical Director Gregory A. Curt, MD, told Oncology News International, lamenting, " I don’t think it’s high on the radar for the physicians."

This seems to be borne out by an accounting of the abstracts presented at the annual meeting of the American Society of Clinical Oncology. Of 3,127 abstracts, only 13 focused on cancer-related fatigue. Yet fatigue is the most prevalent side effect of chemotherapy, affecting more people and lasting longer than pain, nausea, and vomiting, according to a telephone survey of 379 cancer patients sponsored by The Fatigue Coalition.

Dr. Curt said that physicians and patients often don’t talk about cancer-related fatigue because they think nothing can be done about it. That’s not true, he countered, and physicians need to start considering options now that pain, nausea, and vomiting are yielding to treatment. Commenting on the survey, he remarked: "Most oncologists thought pain was more important than fatigue, but patients thought fatigue was more important than pain."

Survey Results

The survey was the second conducted by The Fatigue Coalition, a multidisciplinary group of practitioners, researchers, and patient advocates working to develop diagnosis and treatment guidelines. The first survey concluded that fatigue was undertreated and seldom discussed. Major findings of the new study are listed below.

76% of all cancer patients who responded experienced fatigue at least a few days each month during their most recent chemotherapy and 30% were fatigued every day.

91% of patients experiencing fatigue said it prevented a "normal" life and 85% changed their daily routine as a result.

75% of patients who held jobs said fatigue made them change their employment status in ways ranging from taking sick or vacation days to going on disability or quitting work.

65% of all patients who responded said that their fatigue caused a caregiver to take at least 1 day off work in a typical month.

One of the most surprising findings for Dr. Curt was that some patients complained of fatigue as long as 2 years after treatment. He said he does not know the cause.

While most patients (79%) discussed fatigue with their physicians, nearly half (45%) of the patients did not believe anything could be done about their fatigue and 40% said they received no recommendation in response. Among those who did receive recommendations, the most common suggestion was bed rest or relaxation (37%). Yet according to Dr. Curt, rest "is one of the worst things to do. You get deconditioned."

Other suggestions were diet or nutrition (11%), vitamins (7%), and prescription drugs (6%).

Range of Remedies

The problem of fatigue is complex, Dr. Curt acknowledged. Patients are tired because they are sick, and they are receiving strong therapies that can also cause fatigue. Yet fatigue can be addressed, he noted, citing the work of Russell K. Portenoy, MD, of Beth Israel Medical Center in New York City.

Physicians should first try to ascertain why the patient is fatigued, Dr. Curt said. The range of remedies now available includes light exercise, cutting out daytime naps, and creating a nighttime routine around a hot bath and warm milk to promote sound sleep at night. For some patients, treatment of anemia should be considered, Dr. Curt advised. If a patient is taking a narcotic for pain relief, the medication might be titrated to a lower dose or balanced with a stimulant, he said.

Although fatigue is still by and large neglected, Dr. Curt was optimistic that it will receive more attention as other chemotherapy side effects become less onerous. "We are in the same phase of treating cancer-related fatigue, as we were in treating nausea and vomiting 15 years ago and pain 10 years ago." he said "I remember when the first drugs that were really good at treating nausea and vomiting came out, oncologists were really worried that the chemotherapy wasn’t working because the patients weren’t getting sick. Sometimes we associate side effects of our drugs with the good effect of our drugs, but I think that both in pain research and nausea and vomiting research, we’ve shown that the two can be de-linked."

Future cancer patients will seek out oncologists who pay more attention to the patient’s needs, he predicted. Before that can happen, however, Dr. Curt said more research is needed. "Knowing what the most common causes of cancer related fatigue are and then knowing which of those respond best to specific interventions—we don’t have the foggiest notion about that now," he said.

Articles in this issue

NCI to Expand Its Support for Trials of STI-571
Patients and Physicians Differ on Chemotherapy Expectations
Neoadjuvant Weekly Paclitaxel Ups Breast Cancer Pathologic Complete Response Rates
Concurrent Chemoradiotherapy Helps Preserve Larynx
Once-Daily, Rapid-Onset Morphine Offers Alternative for Those in Severe Pain
FDA Issues New Safeguards for Children in Clinical Trials
Decision Board Helps Breast Cancer Patients Assess Chemotherapy Options, Increases Satisfaction
Over 20% of Breast Cancer Patients Risk Recurrence by Not Taking Their Tamoxifen
Selective Serotonin Reuptake Inhibitors Can Successfully Treat Depression But Not Fatigue in Cancer Patients
Leukemia Society Offers Patient Information on Use of STI-571
Hiking Cigarette Prices Discourages Teens From Taking Up the Habit
Consensus Growing for SV40 Role in Some Mesotheliomas
NCI Launches Randomized Trial of Shark Cartilage in NSCLC
Chemotherapy Common at End of Life
Can Cognitive Dysfunction in Breast Cancer Patients Be Prevented?
Recent Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.
Generally, the communication in academic oncology institutions is favorable; however, when oncologists and pathologists become busy, specimens may be sent to reference laboratories.
Related Content
Advertisement

Findings from the 2025 World Conference on Lung Cancer reflected key updates in the management of NSCLC, SCLC, and other lung cancer types.

WCLC 2025: The Top 5 Takeaways Across Lung Cancer Care

Russ Conroy
September 12th 2025
Article

Findings from the 2025 World Conference on Lung Cancer reflected key updates in the management of NSCLC, SCLC, and other lung cancer types.


A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Elevating Community Oncology Care: Insights From World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 12th 2025
Podcast

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.


The second takeaway is that the type of responses and efficacy that we have seen with these combinations rival what we have in our standard of care armamentarium.

How Promising Are Immunotherapy Combos in Indolent Lymphoma?

Tim Cortese
September 12th 2025
Article

Lorenzo Falchi, MD, highlighted the most important considerations when using novel immunotherapy combination therapies for patients with indolent lymphoma.


Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.

Episode 13: Perspectives on Optimizing Community Care at World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 12th 2025
Podcast

Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.


We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.

Understanding Predictive Markers Drives Ruxolitinib Usage in Myelofibrosis

Tim Cortese
September 12th 2025
Article

According to Francesca Palandri, MD, PhD, ruxolitinib will have a less significant effect in patients with myelofibrosis who have a cytopenic phenotype.


No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.

SC Amivantamab Consistent With IV Formulation in EGFR-Mutated NSCLC

Roman Fabbricatore
September 11th 2025
Article

No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.

Related Content
Advertisement

Findings from the 2025 World Conference on Lung Cancer reflected key updates in the management of NSCLC, SCLC, and other lung cancer types.

WCLC 2025: The Top 5 Takeaways Across Lung Cancer Care

Russ Conroy
September 12th 2025
Article

Findings from the 2025 World Conference on Lung Cancer reflected key updates in the management of NSCLC, SCLC, and other lung cancer types.


A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Elevating Community Oncology Care: Insights From World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 12th 2025
Podcast

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.


The second takeaway is that the type of responses and efficacy that we have seen with these combinations rival what we have in our standard of care armamentarium.

How Promising Are Immunotherapy Combos in Indolent Lymphoma?

Tim Cortese
September 12th 2025
Article

Lorenzo Falchi, MD, highlighted the most important considerations when using novel immunotherapy combination therapies for patients with indolent lymphoma.


Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.

Episode 13: Perspectives on Optimizing Community Care at World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Sam S. Chang MD, MBA;Jeff Yorio, MD
September 12th 2025
Podcast

Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.


We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.

Understanding Predictive Markers Drives Ruxolitinib Usage in Myelofibrosis

Tim Cortese
September 12th 2025
Article

According to Francesca Palandri, MD, PhD, ruxolitinib will have a less significant effect in patients with myelofibrosis who have a cytopenic phenotype.


No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.

SC Amivantamab Consistent With IV Formulation in EGFR-Mutated NSCLC

Roman Fabbricatore
September 11th 2025
Article

No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.